L. Whitesell, E. G. Mimnaugh, B. De Costa, C. E. Myers and L. M. Neckers, “Inhibition of Heat Shock Protein Hsp90-pp60v-src Heteroprotein Complex Formation by Ben-zoquinone Ansamycins: Essential Role for Stress Proteins in Oncogene Transformation,” Proceedings of National Academy of Sciences USA, Vol. 91, No. 18, 1994, pp. 8324-8328.
 A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M. F. Boehm, L. C. Fritz and F. J. Burrows, “High Affinity Conformation of Hsp90 Confers Tumor Selectivity on Hsp90 Inhibitors,” Nature, Vol. 425, No. 6956, 2003, pp. 207-410.
 T. Vanden Berghe, M. Kalai, G. van Loo, W. Declerq and P. Vandenbeele, “Disruption of HSP90 Function Reverts Tumor Necrosis Factor-induced Necrosis to Apoptosis,” Journal of Biological Chemistry, Vol. 278, No. 9, 2003, pp. 5622-5629.
 I. Hostein, D. Robertson, F. DiStefanco, P. Workman, and P. A. Clarke, “Inhibition of Signal Transduction -by the Hsp90 Inhibitor 17-allylamino-17-demethoxygeldanamycin results in Cytostasis and Apoptosis,” Cancer Research, Vol. 61, No. 10, May 2001, pp. 4003-4009.
 A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. M. Ho, T. S. Shen, J. Y. Ko, Lin J. T, Lin B. R, Ming-Shiang W, Yu H. S, Jee S. H, Chen G. S, Chen T. M, Chen C. A, Lai M. K, Lai M. K, Pu Y. S, Pan M. H, Wang Y. J, Tsai C. C and Hsieh C. Y, “Phase I Clinical Trial of Curcumin, a Chemopreventive Agent, in Patients with High-risk or Pre-malignant Lesions,” Antican-cer Research, Vol. 21, No. 4B,2001, pp. 2895-2900.
 A. Duvoix, R. Blasius, S. Delhalle, M. Schnekenburger, F. Morceau, E. Henry, M. Dicato and M. Diederich, “Chemopre-ventive and Therapeutic Effects of Curcumin,” Cancer Letters, Vol. 223, No. 2,2005, pp. 181-190.
 D. Jyothi, P. Vanathi, P. Mangala Gowri, V. Rama Subba Rao, J. Madhusudana Rao and A. S. Sreedhar, “Diferuloylmethane Augments the Cytotoxic Effects of Piplartine Isolated from Piper Chaba,” Toxicology In Vitro, Vol. 23, No. 6, 2009, pp. 1085-1091.
 A. H. Bild, G. Yao, J. T. Chang, Q. Wang, A. Potti, D. Chasse, M. B. Joshi, D. Harpole, J. M. Lancaster, A. Berchuck, J. A. Olson Jr, J. R. Marks, H. K. Dressman, M. West and J. R. Nevins, “Oncogenic Pathway Signatures in Human Cancers as a Guide to Targeted Therapies,” Nature, Vol. 439, No. 7074, 2006, pp. 353-357.
 W. B. Pratt and D. O. Toft, “Regulation of Signaling Protein Function and Trafficking by the Hsp90/hsp70-based Chaperone Machinery,” Experimental Biology and Medicine, Vol. 228, No. 2, 2003, pp.111-133.
 A. S. Sreedhar, P. Vanathi and K. R. Paithankar, “Stress Pro-tein in Biology and Medicine: Evolution, Adaptation and Clinical Evaluation,” International Journal of Pharma and Biosciences, Vol. 1, No. 3, 2010, pp. 1-36.
 D. B. Solit, A. D. Basso, A. B. Olshen, H. I. Scher and N. Rosen, “Inhibition of Heat Shock Protein 90 Function Down-regulates Akt kinase and Sensitizes Tumors to Taxol,” Cancer Research, Vol. 63, No. 9, 2003, pp. 2139-2144.
 A. K. Ghosh, N. E. Kay, C. R. Secreto and T. D. Shanafelt, “Curcumin Inhibits Prosurvival Pathways in Chronic Lympho-cytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG,” Clinical Cancer Re-search, Vol. 15, No. 4, 2009, pp. 1250-1258.
 J. A. Sokoloski, K. Shyam and A. C. Sartorelli, “Induction of the Differentiation of HL-60 Promyelocytic Leukemia Cells by Curcumin in Combination with Low Levels of Vitamin D3,” Oncology Research, Vol. 9, No. 1, 1997, pp. 31-39.
 D. Alesiani, R. Cicconi, M. Mattei, C. Montesano, R. Bei and A. Canini, “Cell Cycle Arrest and Differentiation Induction by 5,7-dimethoxycoumarin in Melanoma Cells. International Journal of Oncology, Vol. 32, No. 2, 2008, pp. 425-434.
 T. V. Rakitina, I. A. Vasilevskaya and P. J. O'Dwyer, “Inhibi-tion of G1/S Transition Potentiates Oxaliplatin-induced Cell Death in Colon Cancer Cell Lines,” Biochemical Pharmacol-ogy, Vol. 73, No. 11, 2007, pp. 1715-1726.
 U. Banerji, N. Sain, S. Y. Sharp, M. Valenti, Y. Asad, R. Rud-dle, F. Raynaud F, M. Walton, S. A. Eccles, I. Judson, A. L. Jackman and P. Workman, “An in Vitro and in Vivo Study of the Combination of the Heat Shock Protein Inhibitor 17-allylamino-17-demethoxygeldanamycin and Carboplatin in Human Ovarian Cancer Models,” Cancer Chemotherapy and Pharmacology, Vol. 62, No. 5, 2008, pp. 769-778.
 N. Sain, B. Krishnan, M. G. Ormerod, A. De Rienzo, W. M. Liu, S. B. Kaye, P. Workman and A. L. Jackman, “Potentiation of Paclitaxel Activity by the HSP90 Inhibitor 17-allylamino-17-demethoxygeldanamycin in Human Ovarian Carcinoma Cell Lines with High Levels of Activated AKT,” Molecular Cancer Therapy, Vol. 5, No. 5, 2006, pp. 1197-1208.
 M. M. Roforth and C. Tan, “Combination of Rapamycin and 17-allylamino-17-demethoxygeldanamycin Abrogates Akt Activation and Potentiates mTOR Blockade in Breast Cancer Cells,” Anticancer Drugs, Vol. 19, No. 7, 2008, pp. 681-688.
 S. Modi, A. T. Stopeck, M. S. Gordon, D. Mendelson, D. B. Solit, R. Bagatell, W. Ma, J. Wheler, N. Rosen, L. Norton, G. F. Cropp, R. G. Johnson, A. L. Hannah and C. A. Hudis, “Com-bination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) is Safe and Active in Trastuzumab-refractory HER-2 Overexpressing Breast Cancer: A Phase I Dose-escalation Study,” Journal of Clinical Oncology, Vol. 25, No. 34, 2007, pp. 5410-5417.
 G. Ravi, P. George, P. Bali, J. Tao, F. Guo, C. Sigua, Y. Li, L. Moscinski, P. Atadja and K. N. Bhalla, “A Combination of Histone Deacetylase Inhibitor LBH589 and the Hsp90 Inhibitor 17-AAG is Highly Active Against Human CML-BC and AML Cells with Constitutively Active Mutant FLT-3 Tyrosine Kinase,” Abstract 3023, Experimental and Molecular Thera-peutics 28: Novel Targets and approaches for angiogenesis and Signaling pathways, 2004.
 D. T. Denhardt, “Oncogene-initiated Aberrant Signaling En-genders the Metastatic Phenotype: Synergistic Transcription Factor Interactions are Targets for cancer therapy,” Critical Reviews in Oncogenesis, Vol. 7, No. 3-4, 1996, pp. 261-291.
 B. H. Choi, C. G. Kim, Y. S. Bae, Y. Lim, Y. H. Lee and S. Y. Shin, “P21 Waf1/Cip1 Expression by Curcumin in U-87MG Human Glioma Cells: Role of Early Growth Response-1 Ex-pression,” Cancer Research, Vol. 68, pp. 1369-1377, 2008.
 A. Khar, A. M. Ali, B. V. V. Pardhasaradhi, C. H. Varalakshmi, R. Anjum and A. L. Kumari, “Induction of Stress Response Renders Human Tumor Cell Lines Resistant to Curcu-min-mediated Apoptosis: Role of Reactive Oxygen Intermedi-ates,” Cell Stress and Chaperones, Vol. 6, No. 4, 2001, pp. 368-376.
 K. Kato, H. Ito and K. Kamei, “Iwamoto I. Stimulation of the stress-induced expression of stress proteins by Curcumin in cultured cells and in rat tissues in vivo,” Cell Stress and Chap-erones, Vol. 3, No. 3, 1998, pp. 152-160.
 A. S. Sreedhar and P. Csermely, “Heat Shock Proteins in the Regulation of Apoptosis: New Strategies in Tumor Therapy. A Comprehensive Review,” Pharmacology and Therapeutics, Vol. 101, No. 3, 2004, pp. 227-257.
 A. B. Kunnumakkara, P. Diagaradjane, P. Anand, K. B. Hari-kumar, A. Deorukhkar, J. Gelovani, S. Guha, S. Krishnan and B. B. Aggarwal, “Curcumin Sensitizes Human Colorectal Cancer to Capecitabine by Modulation of Cyclin D1, COX-2, MMP-9, VEGF and CXCR4 Expression in an Orthotopic Mouse Model,” International Journal of Cancer, Vol. 125, No. 9, 2009, pp. 2187-2197.
 T. Putz, Z. Culig, I. E. Edler, C. Nessler-Menardi, G. Bartsch, H. Grunicke, F. Uberall and H. Klocker, “Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein kinase Pathway in Prostate Cancer Cell Lines,” Cancer Research, Vol. 59, No. 1, 1999, pp. 227-233.